Cargando…

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis

Detalles Bibliográficos
Autores principales:	Sgalla, Giacomo, Magrì, Tonia, Lerede, Marialessia, Comes, Alessia, Richeldi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887424/ https://www.ncbi.nlm.nih.gov/pubmed/35412453 http://dx.doi.org/10.1164/rccm.202112-2765LE

Ejemplares similares

Residual respiratory impairment after COVID-19 pneumonia
por: Lombardi, Francesco, et al.
Publicado: (2021)

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: pathogenesis and management
por: Sgalla, Giacomo, et al.
Publicado: (2018)

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
por: Cerri, Stefania, et al.
Publicado: (2016)

Reply to Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
por: Di Bidino, Rossella, et al.
Publicado: (2022)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
por: Cottin, Vincent, et al.
Publicado: (2014)

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
por: Jones, Mark G., et al.
Publicado: (2016)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kishaba, Tomoo
Publicado: (2019)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2013)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2018)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kim, Dong Soon
Publicado: (2022)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Approach to acute exacerbation of idiopathic pulmonary fibrosis
por: Bhatti, Hammad, et al.
Publicado: (2013)

Acute exacerbations in patients with idiopathic pulmonary fibrosis
por: Kim, Dong Soon
Publicado: (2013)

Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis
por: Sokai, Akihiko, et al.
Publicado: (2017)

Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
por: Kim, Dong Soon
Publicado: (2018)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Coronavirus disease 2019 vaccination‐induced acute exacerbation in idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ktgi3850v0tui4rb6me8qbsuhj